<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000062897" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of penile cancer.</SummaryDescription><SummaryURL xref="http://cancer.gov/types/penile/hp/penile-treatment-pdq">Penile Cancer (PDQ®): Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000038214">penile cancer</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Penile Cancer Treatment (PDQ®)</SummaryTitle><AltTitle TitleType="Short">Penile Cancer Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000038214">penile cancer</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Penile Cancer</Title><SummarySection id="_180"><Title>Incidence and Mortality</Title><Para id="_131">Estimated new cases and deaths from penile  (and other male genital) cancer in the United States in 2015:<Reference refidx="1"/></Para><ItemizedList id="_132" Style="bullet"><ListItem>New cases: 1,820.</ListItem><ListItem>Deaths: 310.</ListItem></ItemizedList></SummarySection><SummarySection id="_196"><Title>Risk Factors</Title><Para id="_197">
Penile cancer is rare in most developed nations, including the United States, where the rate is less than 1 per 100,000 men per year.  Some studies suggest an association between human papillomavirus (HPV) infection and penile cancer.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  Observational studies have shown a lower prevalence of penile HPV in men who have been circumcised (odds ratio, 0.37; 95% confidence interval,  0.16–0.85).<Reference refidx="6"/>  Some, but not all, observational studies also suggest that male newborn circumcision is associated with a decreased risk of penile cancer.<Reference refidx="7"/><Reference refidx="8"/>  According to  published data,  if the relationship is causal, the number needed to treat was about 909 circumcisions to prevent a single case of invasive penile cancer.<Reference refidx="9"/></Para></SummarySection><SummarySection id="_198"><Title>Treatment Overview</Title><Para id="_199">When diagnosed early (<SummaryRef href="CDR0000062897#_122" url="/types/penile/hp/penile-treatment-pdq">stage 0</SummaryRef>, <SummaryRef href="CDR0000062897#_39" url="/types/penile/hp/penile-treatment-pdq">stage I</SummaryRef>, and <SummaryRef href="CDR0000062897#_51" url="/types/penile/hp/penile-treatment-pdq">stage II</SummaryRef>), penile cancer is highly curable. 
Curability decreases sharply for <SummaryRef href="CDR0000062897#_58" url="/types/penile/hp/penile-treatment-pdq">stage III</SummaryRef> and <SummaryRef href="CDR0000062897#_69" url="/types/penile/hp/penile-treatment-pdq">stage IV</SummaryRef>.  Because of the rarity of
this cancer in the United States, clinical trials specifically for penile
cancer are infrequent.  Patients with stage III and stage IV cancer can be candidates
for phase I and phase II clinical trials testing new drugs, biologicals, or surgical
techniques to improve local control and distant metastases.
</Para><Para id="_200">The selection of treatment depends on the following:<Reference refidx="10"/><Reference refidx="11"/></Para><ItemizedList id="_201" Style="bullet"><ListItem>Size.</ListItem><ListItem>Location.</ListItem><ListItem>Invasiveness.</ListItem><ListItem>Stage of the tumor.</ListItem></ItemizedList></SummarySection><ReferenceSection><Citation idx="1">American Cancer Society: Cancer Facts and Figures 2015. Atlanta, Ga: American Cancer Society, 2015. <ExternalRef xref="http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf">Available online</ExternalRef>. Last accessed April 1, 2015.</Citation><Citation idx="2" PMID="11423255" MedlineID="21315857">Del Mistro A, Chieco Bianchi L: HPV-related neoplasias in HIV-infected individuals. Eur J Cancer 37 (10): 1227-35, 2001.</Citation><Citation idx="3" PMID="10510097" MedlineID="99440191">Griffiths TR, Mellon JK: Human papillomavirus and urological tumours: I. Basic science and role in penile cancer. BJU Int 84 (5): 579-86, 1999.</Citation><Citation idx="4" PMID="10478673" MedlineID="99405778">Poblet E, Alfaro L, Fernander-Segoviano P, et al.: Human papillomavirus-associated penile squamous cell carcinoma in HIV-positive patients. Am J Surg Pathol 23 (9): 1119-23, 1999.</Citation><Citation idx="5" PMID="9060069" MedlineID="97213304">Frisch M, van den Brule AJ, Jiwa NM, et al.: HPV-16-positive anal and penile carcinomas in a young man--anogenital 'field effect' in the immunosuppressed male? Scand J Infect Dis 28 (6): 629-32, 1996.</Citation><Citation idx="6" PMID="11948269" MedlineID="21945851">Castellsagué X, Bosch FX, Muñoz N, et al.: Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 346 (15): 1105-12, 2002.</Citation><Citation idx="7" PMID="10699138" MedlineID="20165351">Schoen EJ, Oehrli M, Colby C, et al.: The highly protective effect of newborn circumcision against invasive penile cancer. Pediatrics 105 (3): E36, 2000.</Citation><Citation idx="8" PMID="8634956" MedlineID="96258155">Neonatal circumcision revisited. Fetus and Newborn Committee, Canadian Paediatric Society. CMAJ 154 (6): 769-80, 1996.</Citation><Citation idx="9" PMID="10617731" MedlineID="20102811">Christakis DA, Harvey E, Zerr DM, et al.: A trade-off analysis of routine newborn circumcision. Pediatrics 105 (1 Pt 3): 246-9, 2000.</Citation><Citation idx="10">Trabulsi DJ, Gomella LG: Cancer of the urethra and penis. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 1272-79.</Citation><Citation idx="11">Chao KS, Perez CA: Penis and male urethra. In: Perez CA, Brady LW, eds.: Principles and Practice of Radiation Oncology. 3rd ed. Philadelphia, Pa:  Lippincott-Raven Publishers, 1998, pp 1717-1732.</Citation></ReferenceSection></SummarySection><SummarySection id="_4"><SectMetaData><SpecificDiagnosis ref="CDR0000038214">penile cancer</SpecificDiagnosis><SectionType>Cellular classification--legacy</SectionType></SectMetaData><Title>Cellular Classification of Penile Cancer</Title><Para id="_5">Virtually all penile carcinomas are of squamous cell origin and include the following subtypes: 
</Para><ItemizedList id="_105" Style="bullet"><ListItem>Verrucous carcinoma.<Reference refidx="1"/></ListItem><ListItem>	Warty carcinoma (verruciform).<Reference refidx="2"/></ListItem><ListItem>Basaloid carcinoma.<Reference refidx="3"/> </ListItem></ItemizedList><Para id="_130">Although they are less common subtypes, warty carcinoma and basaloid carcinoma appear to be more highly associated with human papillomaviruses (HPV), particularly HPV 16, than typical squamous cell carcinoma or verrucous carcinoma of the penis.<Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/> </Para><Para id="_106">In addition, neuroendocrine carcinomas can also be seen.<Reference refidx="6"/></Para><ReferenceSection><Citation idx="1" PMID="7822496">Schwartz RA: Verrucous carcinoma of the skin and mucosa. J Am Acad Dermatol 32 (1): 1-21; quiz 22-4, 1995.</Citation><Citation idx="2" PMID="11342782" MedlineID="21240070">Bezerra AL, Lopes A, Landman G, et al.: Clinicopathologic features and human papillomavirus dna prevalence of warty and squamous cell carcinoma of the penis. Am J Surg Pathol 25 (5): 673-8, 2001.</Citation><Citation idx="3" PMID="9630184" MedlineID="98292136">Cubilla AL, Reuter VE, Gregoire L, et al.: Basaloid squamous cell carcinoma: a distinctive human papilloma virus-related penile neoplasm: a report of 20 cases. Am J Surg Pathol 22 (6): 755-61, 1998.</Citation><Citation idx="4" PMID="7473819">Gregoire L, Cubilla AL, Reuter VE, et al.: Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma. J Natl Cancer Inst 87 (22): 1705-9, 1995.</Citation><Citation idx="5" PMID="11583947">Rubin MA, Kleter B, Zhou M, et al.: Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 159 (4): 1211-8, 2001.</Citation><Citation idx="6" PMID="9072615" MedlineID="97188843">Vadmal MS, Steckel J, Teichberg S, et al.: Primary neuroendocrine carcinoma of the penile urethra. J Urol 157 (3): 956-7, 1997.</Citation></ReferenceSection></SummarySection><SummarySection id="_6"><SectMetaData><SpecificDiagnosis ref="CDR0000038214">penile cancer</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for Penile Cancer</Title><SummarySection id="_163"><Title>Definitions of TNM</Title><Para id="_179">The American Joint Committee on Cancer (AJCC) has designated staging by TNM
classification to define penile cancer.<Reference refidx="1"/></Para><Table id="_164"><Title>Table 1.  Primary Tumor (T)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="13.66%"/><ColSpec ColName="col2" ColNum="2" ColWidth="86.33%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Penis. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 447-55.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>b</Superscript>Broad pushing penetration (invasion) is permitted; destructive invasion is against this diagnosis.</entry></Row></TFoot><TBody><Row><entry>TX</entry><entry>Primary tumor cannot be assessed.</entry></Row><Row><entry>T0</entry><entry>No evidence of primary tumor.</entry></Row><Row><entry>Tis</entry><entry>Carcinoma <Emphasis>in situ</Emphasis>.</entry></Row><Row><entry>Ta</entry><entry>Noninvasive verrucous carcinoma.<Superscript>b</Superscript></entry></Row><Row><entry>T1a</entry><entry>Tumor invades subepithelial connective tissue without lymph vascular invasion and is not poorly differentiated (i.e., grade 3–4).</entry></Row><Row><entry>T1b</entry><entry>Tumor invades subepithelial connective tissue with lymph vascular invasion or is poorly differentiated.</entry></Row><Row><entry>T2</entry><entry>Tumor invades corpus spongiosum or cavernosum.</entry></Row><Row><entry>T3</entry><entry>Tumor invades urethra.</entry></Row><Row><entry>T4</entry><entry>Tumor invades other adjacent structures.</entry></Row></TBody></TGroup></Table><Table id="_165"><Title>Table 2.  Regional Lymph Nodes (N)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="27.93%"/><ColSpec ColName="col2" ColNum="2" ColWidth="72.06%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Penis. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 447-55.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>b</Superscript>Clinical stage definition based on palpation, imaging.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>c</Superscript>Pathologic stage definition based on biopsy or surgical excision.</entry></Row></TFoot><TBody><Row><entry Align="Center" NameEnd="col2" NameSt="col1"><Emphasis>Clinical Stage Definition</Emphasis><Superscript>b</Superscript></entry></Row><Row><entry>cNX</entry><entry>Regional lymph nodes cannot be assessed.</entry></Row><Row><entry>cN0</entry><entry>No palpable or visibly enlarged inguinal lymph nodes.</entry></Row><Row><entry>cN1</entry><entry>Palpable mobile unilateral inguinal lymph node.</entry></Row><Row><entry>cN2</entry><entry>Palpable mobile multiple or bilateral inguinal lymph nodes.</entry></Row><Row><entry>cN3</entry><entry>Palpable fixed inguinal nodal mass or pelvic lymphadenopathy unilateral or bilateral.</entry></Row><Row><entry Align="Center" NameEnd="col2" NameSt="col1"><Emphasis>Pathologic Stage Definition</Emphasis><Superscript>c</Superscript></entry></Row><Row><entry>pNX</entry><entry>Regional lymph nodes cannot be assessed.</entry></Row><Row><entry>pN0</entry><entry>No regional lymph node metastasis.</entry></Row><Row><entry>pN1</entry><entry>Metastasis in a single inguinal lymph node.</entry></Row><Row><entry>pN2</entry><entry>Metastases in multiple or bilateral inguinal lymph nodes.</entry></Row><Row><entry>pN3</entry><entry>Extranodal extension of lymph node metastasis or pelvic lymph node(s) unilateral or bilateral.</entry></Row></TBody></TGroup></Table><Table id="_166"><Title>Table 3.  Distant Metastasis (M)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="17.79%"/><ColSpec ColName="col2" ColNum="2" ColWidth="82.20%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Penis. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 447-55.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>b</Superscript>Lymph node metastasis outside of the true pelvis in addition to visceral or bone sites.</entry></Row></TFoot><TBody><Row><entry>M0</entry><entry>No distant metastasis.</entry></Row><Row><entry>M1</entry><entry>Distant metastasis.<Superscript>b</Superscript></entry></Row></TBody></TGroup></Table><Para id="_167"><Strong>Additional Descriptor. </Strong>The m suffix indicates the presence of multiple primary tumors and is recorded in parentheses – e.g., pTa (m) N0M0.<Reference refidx="1"/></Para><Table id="_168"><Title>Table 4.  Anatomic Stage/Prognostic Groups<Superscript>a</Superscript></Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Center">T</entry><entry Align="Center">N</entry><entry Align="Center">M</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Penis. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 447-55.</entry></Row></TFoot><TBody><Row><entry MoreRows="1">0</entry><entry>Tis</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>Ta</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>I</entry><entry>T1a</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry MoreRows="2">II</entry><entry>T1b</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>T2</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>T3</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>IIIa</entry><entry>T1–3</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>IIIb</entry><entry>T1–3</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry MoreRows="2"> IV</entry><entry>T4</entry><entry>Any N</entry><entry>M0</entry></Row><Row><entry>Any T</entry><entry>N3</entry><entry>M0</entry></Row><Row><entry>Any T</entry><entry>Any N</entry><entry>M1</entry></Row></TBody></TGroup></Table></SummarySection><ReferenceSection><Citation idx="1">Penis. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 447-55.</Citation></ReferenceSection></SummarySection><SummarySection id="_122"><SectMetaData><SpecificDiagnosis ref="CDR0000566317">stage 0 penile cancer</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Stage 0 Penile Cancer</Title><Para id="_184"><Strong>Stage 0 penile cancer is defined by the following TNM classifications:<Reference refidx="1"/></Strong></Para><ItemizedList id="_124" Style="bullet"><ListItem>Tis, N0, M0</ListItem><ListItem>Ta, N0, M0</ListItem></ItemizedList><Para id="_125">Carcinoma <Emphasis>in situ</Emphasis> of the penis is referred to as erythroplasia of Queyrat when it occurs on the glans, and Bowen disease when it occurs on the penile shaft.  These precursor lesions progress to invasive squamous cell carcinoma in 5% to 15% of cases.  In case series studies, human papillomavirus DNA has been detected in the majority of these lesions.<Reference refidx="2"/><Reference refidx="3"/> With no data from clinical trials in this disease stage, treatment recommendations are largely based on case reports and case series involving limited numbers of patients.</Para><Para id="_126"><Strong>Treatment options:
</Strong></Para><OrderedList id="_127" Style="Arabic" Compact="No"><ListItem>Surgical excision can result in scarring, deformity, and impaired function.  To minimize these effects, Mohs micrographic surgery, which involves the excision of successive horizontal layers of tissue with microscopic examination of each layer in frozen section, has been used in patients with <Emphasis>in situ</Emphasis> and invasive penile cancers.<Reference refidx="4"/><Reference refidx="5"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</ListItem><ListItem>Topical application of 5-fluorouracil cream has been reported to be effective in cases of erythroplasia of Queyrat <Reference refidx="6"/> and Bowen disease.<Reference refidx="7"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</ListItem><ListItem>	Imiquimod 5% cream is a topical immune response modifier that has been reported to be effective with good cosmetic and functional results.<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</ListItem><ListItem>Laser therapy with Nd:YAG or CO<Subscript>2</Subscript> lasers has also been reported to result in excellent cosmetic results.<Reference refidx="11"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</ListItem><ListItem>Cryosurgery has been reported to result in good cosmetic results in patients with erythroplasia of Queyrat and verrucous penile carcinoma.<Reference refidx="12"/><Reference refidx="13"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</ListItem></OrderedList><SummarySection id="_TrialSearch_122_sid_4"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_122_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=566317&amp;tt=1&amp;format=2&amp;cn=1">stage 0 penile cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_122_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1">Penis. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 447-55.</Citation><Citation idx="2" PMID="7637047">Cupp MR, Malek RS, Goellner JR, et al.: The detection of human papillomavirus deoxyribonucleic acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis. J Urol 154 (3): 1024-9, 1995.</Citation><Citation idx="3" PMID="11583947">Rubin MA, Kleter B, Zhou M, et al.: Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 159 (4): 1211-8, 2001.</Citation><Citation idx="4" PMID="3999220" MedlineID="85211096">Mohs FE, Snow SN, Messing EM, et al.: Microscopically controlled surgery in the treatment of carcinoma of the penis. J Urol 133 (6): 961-6, 1985.</Citation><Citation idx="5" PMID="2040751">Moritz DL, Lynch WS: Extensive Bowen's disease of the penile shaft treated with fresh tissue Mohs micrographic surgery in two separate operations. J Dermatol Surg Oncol 17 (4): 374-8, 1991.</Citation><Citation idx="6" PMID="991073">Goette DK, Carson TE: Erythroplasia of Queyrat: treatment with topical 5-fluorouracil. Cancer 38 (4): 1498-502, 1976.</Citation><Citation idx="7" PMID="936382">Tolia BM, Castro VL, Mouded IM, et al.: Bowen's disease of shaft of penis. Successful treatment with 5-fluorouracil. Urology 7 (6): 617-9, 1976.</Citation><Citation idx="8" PMID="14616803">Danielsen AG, Sand C, Weismann K: Treatment of Bowen's disease of the penis with imiquimod 5% cream. Clin Exp Dermatol 28 (Suppl 1): 7-9, 2003.</Citation><Citation idx="9" PMID="14616802">Micali G, Nasca MR, Tedeschi A: Topical treatment of intraepithelial penile carcinoma with imiquimod. Clin Exp Dermatol 28 (Suppl 1): 4-6, 2003.</Citation><Citation idx="10" PMID="11907505">Schroeder TL, Sengelmann RD: Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol 46 (4): 545-8, 2002.</Citation><Citation idx="11" PMID="11586199">van Bezooijen BP, Horenblas S, Meinhardt W, et al.: Laser therapy for carcinoma in situ of the penis. J Urol 166 (5): 1670-1, 2001.</Citation><Citation idx="12" PMID="12187233">Michelman FA, Filho AC, Moraes AM: Verrucous carcinoma of the penis treated with cryosurgery. J Urol 168 (3): 1096-7, 2002.</Citation><Citation idx="13" PMID="7073983">Sonnex TS, Ralfs IG, Plaza de Lanza M, et al.: Treatment of erythroplasia of Queyrat with liquid nitrogen cryosurgery. Br J Dermatol 106 (5): 581-4, 1982.</Citation></ReferenceSection></SummarySection><SummarySection id="_39"><SectMetaData><SpecificDiagnosis ref="CDR0000038222">stage I penile cancer</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Stage I Penile Cancer</Title><Para id="_185"><Strong>Stage I penile cancer is defined by the following TNM classification:<Reference refidx="1"/></Strong></Para><ItemizedList id="_87" Style="bullet"><ListItem>T1a, N0, M0</ListItem></ItemizedList><Para id="_41">Stage I penile cancer is curable.<Reference refidx="2"/>
</Para><Para id="_42"><Strong>Standard treatment options:
</Strong></Para><OrderedList id="_79" Style="Arabic" Compact="No"><ListItem>For lesions limited to the foreskin, wide local excision with circumcision may
be adequate therapy for control.
</ListItem><ListItem>For infiltrating tumors of the glans with or without involvement of the
adjacent skin, the choice of therapy is dictated by tumor size, extent of
infiltration, and degree of tumor destruction of normal tissue.  Equivalent
therapeutic options include:
<ItemizedList id="_47" Style="bullet"><ListItem>Penile amputation.<Reference refidx="3"/>
</ListItem>
<ListItem>Radiation  therapy (i.e., external-beam radiation therapy and  brachytherapy).<Reference refidx="4"/><Reference refidx="5"/>
</ListItem>
<ListItem>Microscopically controlled surgery.<Reference refidx="6"/>
</ListItem>
</ItemizedList></ListItem></OrderedList><Para id="_48"><Strong>Treatment options under clinical evaluation:
</Strong></Para><ItemizedList id="_80" Style="bullet"><ListItem>Nd:YAG laser therapy has offered excellent control/cure with preservation of
cosmetic appearance and sexual function.<Reference refidx="7"/><Reference refidx="8"/>  
</ListItem></ItemizedList><Para id="_50">Because of the high incidence of microscopic node metastases, elective
adjunctive inguinal dissection of clinically uninvolved (negative) lymph nodes
in conjunction with amputation is often used for patients with poorly
differentiated tumors.  Lymphadenectomy  can carry substantial
morbidity, such as infection, skin necrosis, wound breakdown, chronic edema,
and even a low, but finite, mortality rate.  The impact of prophylactic
lymphadenectomy on survival is not known.  For these reasons, opinions vary on its use.<Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/>
</Para><SummarySection id="_TrialSearch_39_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_39_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38222&amp;tt=1&amp;format=2&amp;cn=1">stage I penile cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_39_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1">Penis. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 447-55.</Citation><Citation idx="2">Harty JI, Catalona WJ: Carcinoma of the penis. In: Javadpour N, ed.: Principles and Management of Urologic Cancer. 2nd ed. Baltimore, Md: Williams and Wilkins, 1983, pp 581-597.</Citation><Citation idx="3">Lynch DF, Pettaway CA: Tumors of the penis. In: Walsh PC, Retik AB, Vaughan ED, et al., eds.: Campbell's Urology. 8th ed. Philadelphia: Saunders, 2002, pp 2945-2947.</Citation><Citation idx="4">Chao KS, Perez CA: Penis and male urethra. In: Perez CA, Brady LW, eds.: Principles and Practice of Radiation Oncology. 3rd ed. Philadelphia, Pa:  Lippincott-Raven Publishers, 1998, pp 1717-1732.</Citation><Citation idx="5" PMID="8454480" MedlineID="93202967">McLean M, Akl AM, Warde P, et al.: The results of primary radiation therapy in the management of squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys 25 (4): 623-8, 1993.</Citation><Citation idx="6" PMID="3999220" MedlineID="85211096">Mohs FE, Snow SN, Messing EM, et al.: Microscopically controlled surgery in the treatment of carcinoma of the penis. J Urol 133 (6): 961-6, 1985.</Citation><Citation idx="7">Smith JA Jr.: Lasers in clinical urologic surgery. In: Dixon JA, ed.: Surgical Application of Lasers. 2nd ed. Chicago, Ill: Year Book Medical Publishers, Inc., 1987, pp 218-237.</Citation><Citation idx="8" PMID="1593683" MedlineID="92277742">Horenblas S, van Tinteren H, Delemarre JF, et al.: Squamous cell carcinoma of the penis. II. Treatment of the primary tumor. J Urol 147 (6): 1533-8, 1992.</Citation><Citation idx="9" PMID="8627839" MedlineID="96186040">Theodorescu D, Russo P, Zhang ZF, et al.: Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. J Urol 155 (5): 1626-31, 1996.</Citation><Citation idx="10" PMID="8705227" MedlineID="96334886">Lindegaard JC, Nielsen OS, Lundbeck FA, et al.: A retrospective analysis of 82 cases of cancer of the penis. Br J Urol 77 (6): 883-90, 1996.</Citation><Citation idx="11" PMID="7512656" MedlineID="94210622">Ornellas AA, Seixas AL, Marota A, et al.: Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol 151 (5): 1244-9, 1994.</Citation><Citation idx="12" PMID="1746081" MedlineID="92081133">Young MJ, Reda DJ, Waters WB: Penile carcinoma: a twenty-five-year experience. Urology 38 (6): 529-32, 1991.</Citation></ReferenceSection></SummarySection><SummarySection id="_51"><SectMetaData><SpecificDiagnosis ref="CDR0000038233">stage II penile cancer</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Stage II Penile Cancer</Title><Para id="_186"><Strong>Stage II penile cancer is defined by the following TNM classifications:<Reference refidx="1"/></Strong></Para><ItemizedList id="_88" Style="bullet"><ListItem>T1b, N0, M0</ListItem><ListItem>T2, N0, M0</ListItem><ListItem>T3, N0, M0</ListItem></ItemizedList><Para id="_53"><Strong>Standard treatment options:
</Strong></Para><ItemizedList id="_81" Style="bullet"><ListItem>Stage II penile cancer is most frequently managed by penile amputation for
local control.  Whether the amputation is partial, total, or radical will
depend on the extent and location of the neoplasm.  External-beam radiation therapy and brachytherapy with
surgical salvage are alternative approaches.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/></ListItem></ItemizedList><Para id="_55"><Strong>Treatment options under clinical evaluation:
</Strong></Para><ItemizedList id="_82" Style="bullet"><ListItem>Nd:YAG laser therapy has been used to preserve the penis in selected patients
with small lesions.<Reference refidx="7"/></ListItem></ItemizedList><Para id="_57">Because of the high incidence of microscopic node metastases, elective
adjunctive dissection of clinically uninvolved (negative) lymph nodes in
conjunction with amputation is often used for patients with poorly
differentiated tumors.   Lymphadenectomy,  can carry substantial
morbidity, such as infection, skin necrosis, wound breakdown, chronic edema,
and even a low, but finite, mortality rate.  The impact of prophylactic
lymphadenectomy on survival is not known.<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/>
</Para><Para id="_142">To reduce the morbidity associated with prophylactic lymphadenectomy, dynamic sentinel node biopsy is being used in patients with stage T2 clinically node-negative penile cancer.  One retrospective single-institution study of 22 patients reported a  false-negative rate of 11%.<Reference refidx="12"/></Para><SummarySection id="_TrialSearch_51_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_51_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38233&amp;tt=1&amp;format=2&amp;cn=1">stage II penile cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_51_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1">Penis. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 447-55.</Citation><Citation idx="2">Harty JI, Catalona WJ: Carcinoma of the penis. In: Javadpour N, ed.: Principles and Management of Urologic Cancer. 2nd ed. Baltimore, Md: Williams and Wilkins, 1983, pp 581-597.</Citation><Citation idx="3">Schellhammer PF, Spaulding JT: Carcinoma of the penis. In: Paulson DF, ed.: Genitourinary Surgery. Vol. 2. New York: Churchill Livingston, 1984, pp 629-654.</Citation><Citation idx="4">Johnson DE, Lo RK: Tumors of the penis, urethra, and scrotum. In: deKernion JB, Paulson DF, eds.: Genitourinary Cancer Management. Philadelphia, Pa: Lea and Febiger, 1987, pp 219-258.</Citation><Citation idx="5" PMID="8454480" MedlineID="93202967">McLean M, Akl AM, Warde P, et al.: The results of primary radiation therapy in the management of squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys 25 (4): 623-8, 1993.</Citation><Citation idx="6" PMID="15890588">Crook JM, Jezioranski J, Grimard L, et al.: Penile brachytherapy: results for 49 patients. Int J Radiat Oncol Biol Phys 62 (2): 460-7, 2005.</Citation><Citation idx="7" PMID="1593683" MedlineID="92277742">Horenblas S, van Tinteren H, Delemarre JF, et al.: Squamous cell carcinoma of the penis. II. Treatment of the primary tumor. J Urol 147 (6): 1533-8, 1992.</Citation><Citation idx="8" PMID="8627839" MedlineID="96186040">Theodorescu D, Russo P, Zhang ZF, et al.: Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. J Urol 155 (5): 1626-31, 1996.</Citation><Citation idx="9" PMID="8705227" MedlineID="96334886">Lindegaard JC, Nielsen OS, Lundbeck FA, et al.: A retrospective analysis of 82 cases of cancer of the penis. Br J Urol 77 (6): 883-90, 1996.</Citation><Citation idx="10" PMID="7512656" MedlineID="94210622">Ornellas AA, Seixas AL, Marota A, et al.: Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol 151 (5): 1244-9, 1994.</Citation><Citation idx="11" PMID="1746081" MedlineID="92081133">Young MJ, Reda DJ, Waters WB: Penile carcinoma: a twenty-five-year experience. Urology 38 (6): 529-32, 1991.</Citation><Citation idx="12" PMID="16360457">Perdonà S, Autorino R, De Sio M, et al.: Dynamic sentinel node biopsy in clinically node-negative penile cancer versus radical inguinal lymphadenectomy: a comparative study. Urology 66 (6): 1282-6, 2005.</Citation></ReferenceSection></SummarySection><SummarySection id="_58"><SectMetaData><SpecificDiagnosis ref="CDR0000038243">stage III penile cancer</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Stage III Penile Cancer</Title><Para id="_187"><Strong>Stage III penile cancer is defined by the following TNM classifications:<Reference refidx="1"/></Strong></Para><ItemizedList id="_89" Style="bullet"><ListItem>T1–3, N1, M0</ListItem><ListItem>T1–3, N2, M0</ListItem></ItemizedList><Para id="_60">Inguinal adenopathy in patients with penile cancer is common but may be the
result of infection rather than neoplasm.  If palpable enlarged lymph nodes
exist 3 or more weeks after removal of the infected primary lesion and completion of a
course of antibiotic therapy, bilateral inguinal lymph node dissection should
be performed.
</Para><Para id="_61">In cases of proven regional inguinal lymph node metastasis without evidence of
distant spread, bilateral ilioinguinal dissection is the treatment of
choice.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  Since many patients with positive lymph nodes are not
cured, clinical trials may be appropriate.
</Para><Para id="_62"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_83" Style="Arabic" Compact="No"><ListItem>Clinically evident regional lymph node metastasis without evidence of
distant spread is an indication for bilateral ilioinguinal lymph node
dissection after penile amputation.<Reference refidx="6"/></ListItem><ListItem>Radiation therapy may be considered as an alternative to lymph node
dissection in patients who are not surgical candidates.</ListItem><ListItem>Postoperative radiation therapy may decrease incidence of inguinal recurrences.</ListItem></OrderedList><Para id="_66"><Strong>Treatment options under clinical evaluation:</Strong>
</Para><ItemizedList id="_84" Style="bullet"><ListItem>Clinical trials using radiosensitizers or cytotoxic drugs are appropriate.  A
combination of vincristine, bleomycin, and methotrexate has been effective as
both neoadjuvant and adjuvant therapy.<Reference refidx="7"/>  Cisplatin (100 mg/m²) as neoadjuvant therapy plus continuous-infusion 5-fluorouracil has also
been shown to be effective.<Reference refidx="6"/>  Single-agent cisplatin (50 mg/m<Superscript>2</Superscript>) was tested in a large trial and was found to be ineffective.<Reference refidx="8"/></ListItem></ItemizedList><Para id="_68">Because of the high incidence of microscopic node metastases, adjunctive
inguinal dissection of clinically uninvolved (negative) lymph nodes in
conjunction with amputation is often used for patients with poorly
differentiated tumors. Lymphadenectomy  can carry substantial
morbidity, such as infection, skin necrosis, wound breakdown, chronic edema,
and even a low, but finite, mortality rate.  The impact of prophylactic
lymphadenectomy on survival is not known.  <Reference refidx="3"/><Reference refidx="4"/><Reference refidx="9"/><Reference refidx="10"/>
</Para><Para id="_146">To reduce the morbidity associated with prophylactic lymphadenectomy, dynamic sentinel node biopsy is being used in patients with stage T2 and stage T3 clinically node-negative penile cancer.  One retrospective single-institution study of 22 patients reported a  false-negative rate of 11%.<Reference refidx="11"/></Para><SummarySection id="_TrialSearch_58_sid_7"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_58_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38243&amp;tt=1&amp;format=2&amp;cn=1">stage III penile cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_58_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1">Penis. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 447-55.</Citation><Citation idx="2">Harty JI, Catalona WJ: Carcinoma of the penis. In: Javadpour N, ed.: Principles and Management of Urologic Cancer. 2nd ed. Baltimore, Md: Williams and Wilkins, 1983, pp 581-597.</Citation><Citation idx="3" PMID="8627839" MedlineID="96186040">Theodorescu D, Russo P, Zhang ZF, et al.: Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. J Urol 155 (5): 1626-31, 1996.</Citation><Citation idx="4" PMID="8705227" MedlineID="96334886">Lindegaard JC, Nielsen OS, Lundbeck FA, et al.: A retrospective analysis of 82 cases of cancer of the penis. Br J Urol 77 (6): 883-90, 1996.</Citation><Citation idx="5">Lynch DF, Pettaway CA: Tumors of the penis. In: Walsh PC, Retik AB, Vaughan ED, et al., eds.: Campbell's Urology. 8th ed. Philadelphia: Saunders, 2002, pp 2945-2947.</Citation><Citation idx="6">Fisher HA, Barada JH, Horton J, et al.: Neoadjuvant therapy with cisplatin and 5-fluorouracil for stage III squamous cell carcinoma of the penis. [Abstract] J Urol  143(4 Suppl): A-653, 352A, 1990.</Citation><Citation idx="7" PMID="2466471" MedlineID="89166200">Pizzocaro G, Piva L: Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 27 (6b): 823-4, 1988.</Citation><Citation idx="8" PMID="2642312" MedlineID="89068929">Gagliano RG, Blumenstein BA, Crawford ED, et al.: cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. J Urol 141 (1): 66-7, 1989.</Citation><Citation idx="9" PMID="7512656" MedlineID="94210622">Ornellas AA, Seixas AL, Marota A, et al.: Surgical treatment of invasive squamous cell carcinoma of the penis: retrospective analysis of 350 cases. J Urol 151 (5): 1244-9, 1994.</Citation><Citation idx="10" PMID="1746081" MedlineID="92081133">Young MJ, Reda DJ, Waters WB: Penile carcinoma: a twenty-five-year experience. Urology 38 (6): 529-32, 1991.</Citation><Citation idx="11" PMID="16360457">Perdonà S, Autorino R, De Sio M, et al.: Dynamic sentinel node biopsy in clinically node-negative penile cancer versus radical inguinal lymphadenectomy: a comparative study. Urology 66 (6): 1282-6, 2005.</Citation></ReferenceSection></SummarySection><SummarySection id="_69"><SectMetaData><SpecificDiagnosis ref="CDR0000038252">stage IV penile cancer</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Stage IV Penile Cancer</Title><Para id="_188"><Strong>Stage IV penile cancer is defined by the following TNM classifications:<Reference refidx="1"/></Strong></Para><ItemizedList id="_90" Style="bullet"><ListItem>T4, Any N, M0</ListItem><ListItem>Any T, N3, M0</ListItem><ListItem>Any T, Any N, M1</ListItem></ItemizedList><Para id="_71">No standard treatment  exists that is curative for patients with stage IV penile cancer. 
Therapy is directed at palliation, which may be achieved either with surgery or
radiation therapy.
</Para><Para id="_72"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_85" Style="Arabic" Compact="No"><ListItem>Palliative surgery may be considered for control of the local penile lesion
and even for the prevention of the necrosis, infection, and hemorrhage that
can result from neglected regional adenopathy.
</ListItem><ListItem>Radiation therapy may be palliative for the primary tumor, regional adenopathy,
and bone metastases.
</ListItem></OrderedList><Para id="_75"><Strong>Treatment options under clinical evaluation:
</Strong></Para><ItemizedList id="_86" Style="bullet"><ListItem>Clinical trials combining chemotherapy with palliative methods of local control
are appropriate for such patients (tested chemotherapeutic drugs with some
efficacy include vincristine, cisplatin, methotrexate, and bleomycin).  The
combination of vincristine, bleomycin, and methotrexate has been effective both
as adjuvant and neoadjuvant therapy.<Reference refidx="2"/></ListItem></ItemizedList><SummarySection id="_TrialSearch_69_sid_8"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_69_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38252&amp;tt=1&amp;format=2&amp;cn=1">stage IV penile cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_69_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1">Penis. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 447-55.</Citation><Citation idx="2" PMID="2466471" MedlineID="89166200">Pizzocaro G, Piva L: Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 27 (6b): 823-4, 1988.</Citation></ReferenceSection></SummarySection><SummarySection id="_77"><SectMetaData><SpecificDiagnosis ref="CDR0000038263">recurrent penile cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Recurrent Penile Cancer</Title><Para id="_78">Locally recurrent disease can be approached by surgery or radiation therapy. 
If the initial treatment of radiation therapy fails,  patients are often salvaged by
penile amputation.  Patients with nodal recurrences that are not controllable
by local measures are candidates for phase I and phase II clinical trials testing new
biologicals and chemotherapeutic agents.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/></Para><SummarySection id="_TrialSearch_77_sid_9"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_77_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38263&amp;tt=1&amp;format=2&amp;cn=1">recurrent penile cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_77_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="2466471" MedlineID="89166200">Pizzocaro G, Piva L: Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 27 (6b): 823-4, 1988.</Citation><Citation idx="2" PMID="6206239" MedlineID="84292484">Ahmed T, Sklaroff R, Yagoda A: Sequential trials of methotrexate, cisplatin and bleomycin for penile cancer. J Urol 132 (3): 465-8, 1984.</Citation><Citation idx="3" PMID="1719241" MedlineID="92046406">Dexeus FH, Logothetis CJ, Sella A, et al.: Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol 146 (5): 1284-7, 1991.</Citation><Citation idx="4">Fisher HA, Barada JH, Horton J, et al.: Neoadjuvant therapy with cisplatin and 5-fluorouracil for stage III squamous cell carcinoma of the penis. [Abstract] J Urol  143(4 Suppl): A-653, 352A, 1990.</Citation><Citation idx="5" PMID="2297633" MedlineID="90124109">Hussein AM, Benedetto P, Sridhar KS: Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer 65 (3): 433-8, 1990.</Citation></ReferenceSection></SummarySection><SummarySection id="_97"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (02/05/2015)</Title><Para id="_98">The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.
</Para><Para id="_204"><Strong><SummaryRef href="CDR0000062897#_1" url="/types/penile/hp/penile-treatment-pdq">General Information About Penile Cancer</SummaryRef></Strong></Para><Para id="_205">Updated <SummaryRef href="CDR0000062897#_131" url="/types/penile/hp/penile-treatment-pdq">statistics</SummaryRef> with estimated new cases and deaths for 2015 (cited American Cancer Society as reference 1).</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062897#_AboutThis_1" url="http://www.cancer.gov/types/penile/hp/penile-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of penile cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Penile Cancer Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Franco M. Muggia, MD (New York University Medical Center)</ListItem><ListItem>Andrew Stephenson, MD (Cleveland Clinic)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Penile Cancer Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/penile/hp/penile-treatment-pdq">http://www.cancer.gov/types/penile/hp/penile-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateLastModified>2015-02-05</DateLastModified></Summary>
